NetworkNewsBreaks – InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) Could Prove to Be a Cannabis Biotech Unicorn

The recent solar eclipse that enthralled the world has come and gone, but no shadow of an eclipse is on the horizon to blot out the progress of InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). As peer valuations have soared in Canada’s cannabis market, InMed continues its promising R&D efforts into the therapeutic benefits of marijuana, and this Vancouver, Canada-based company may just prove to be one of the unicorns of Canada’s cannabis biotech market. An excerpt from an article further discussing this reads: “InMed Pharmaceuticals has more to offer than the typical drug discovery and development company. Its triple play comprises a proprietary technology based on biosynthesis, a bioinformatics system, and a robust drug development pipeline, any one of which may propel this innovative biotech to success. The company has developed a process to manufacture cannabinoids by applying cannabinoid DNA to Escherichia-coli (E. coli) bacteria. The E. coli DNA is then removed, leaving just the cannabinoid DNA, which can then replicate in a process known as biosynthesis. Biosynthesis is widely employed in the pharmaceutical industry and is used, for example, to manufacture the insulin upon which millions of diabetics rely.”

To view the full article, visit http://nnw.fm/3Iu5f

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s